Ablative Therapies for Hepatocellular Carcinoma

Ablative therapies have become central to the management of hepatocellular carcinoma (HCC), offering minimally invasive alternatives to surgery for early-stage and unresectable tumours. These techniques employ thermal energy (radiofrequency ablation, microwave ablation, laser ablation), chemical agents (percutaneous ethanol injection), freezing (cryoablation) or electrical pulses (irreversible electroporation) to destroy malignant tissue. Choice of modality is guided by tumour size, location, liver function and patient comorbidities. Radiofrequency ablation (RFA) and microwave ablation (MWA) achieve coagulative necrosis through heat generation, while ethanol injection induces dehydration and protein denaturation. Cryoablation employs controlled ice formation, and emerging approaches such as high-intensity focused ultrasound offer non-invasive control. Advances in imaging guidance and formulation chemistry—such as gel-phase ethanol—have improved precision and reduced collateral injury. These therapies can serve as bridges to transplantation, palliate symptoms or achieve curative intent in carefully selected patients. Integration with systemic and immunotherapies is under investigation to tackle residual disease and enhance long-term control.

Research from Nature Portfolio

One seminal report described the incorporation of ethyl cellulose into ethanol ablation to form a viscous gel within the tumour microenvironment. In preclinical studies this gel-phase ethanol achieved complete regression of chemically induced epithelial tumours in a hamster model using only one-quarter of the usual volume, compared with pure ethanol controls. By retaining localisation and reducing fluid dispersion, this enhanced formulation offers a low-cost, high-efficacy strategy for resource-limited settings and has spurred subsequent optimisation of gel-based chemical ablations for HCC.

Ablative Therapies for Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in ablative therapies for hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Ablation: Targeted destruction of tissue using thermal, chemical or electrical methods.

Radiofrequency ablation (RFA): Thermal ablation employing high-frequency alternating current to induce coagulative necrosis.

Percutaneous ethanol injection (PEI): Chemical ablation involving the direct injection of ethanol to induce cellular dehydration and necrosis.

Microwave ablation (MWA): Thermal ablation using electromagnetic microwaves to generate heat and destroy tumour cells.

Theranostic: Combined diagnostic and therapeutic strategy often involving targeted imaging agents and corresponding treatments.

Transformer model: Deep learning architecture using self-attention mechanisms for predictive tasks on complex data.

Radioligand: Radioactively labelled molecule that binds selectively to a biological target for imaging or therapy.

Ethyl cellulose-ethanol (ECE): A viscous gel formulation that enhances retention and distribution of ethanol in tissue during ablation.

References

1. Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection. Theranostics (2024).
2. Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation. Hepatology International (2023).
3. Determining the Relationship between Delivery Parameters and Ablation Distribution for Novel Gel Ethanol Percutaneous Therapy in Ex Vivo Swine Liver. Polymers (2024).
4. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (2019).
5. Development of enhanced ethanol ablation as an alternative to surgery in treatment of superficial solid tumors. Scientific Reports (2017).